Novartis Sees Targeted Combinations As Wave Of The Future In Oncology
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis’ targeted combination strategy in particular leverages its “strong” pipeline in agents acting on the PI3K, RAS, RAF and MEK pathways.